Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth, Predictive Bio Partner on Bladder Cancer Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today announced it has licensed certain DNA methylation biomarkers to Predictive Biosciences for the development of bladder cancer diagnostics.

Under the deal, Predictive has exclusive rights in the United States to use the biomarkers to develop the tests and will pay MDxHealth upfront and milestone payments as well as royalties on net sales.

MDxHealth, which is undergoing a restructuring, retains the worldwide exclusive rights to the markers for tissue-based bladder cancer tests. No further terms were disclosed.

"We believe that collaborating with partners who focus on one disease area is a better way to leverage our biomarkers for cancer screening as these dedicated companies stand a greater chance of bringing these products successfully to market," MDxHealth CEO Jan Groen said in a statement.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.